Editorial Commentary: The Acellular Osteochondral Allograft, the Emperor Has New Clothes.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29198358.
- Also identified by DOI 10.1016/j.arthro.2017.08.270.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
For larger lesions (>2.5-cm<sup>2</sup>), clinical evidence and practice have shown that fresh osteochondral allograft have good durability, with 88% return to sport and greater than 75% 10-year survival rates for treatment of large femoral condyle lesions. That said, the use of fresh osteochondral allografts in clinical practice is limited by the availability of acceptable donor tissues for eligible patients in a timely fashion. Significant diminution of chondrocyte viability and density occurs during the preservation and storage period. All osteochondral allografts are not equal in performance and outcome. Chondrocyte density and viability are critical for successful transplantation and outcome in the short and long term. This commentary highlights the high failure rates of tissue when it is acellular.
Medical subject headings
- Cartilage, Articular
Anatomy
- knee